NVCR News and Press, NovoCure Limited From 03/11/24

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ...

2024-02-22 12:15:13 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2023 Earnings Call Feb 22, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2023 Earnings Call Transcript

2024-02-21 11:34:50 ET More on NovoCure NovoCure: Stay Cautious Amid Positive Signs NovoCure Tumor Treating Fields accepted for FDA review Novocure reports better-than-expected preliminary Q4, FY revenue Seeking Alpha’s Quant Rating on NovoCure ...

2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...

2024-01-19 17:47:40 ET Summary NovoCure's FDA application for TTF in NSCLC accepted; approval expected in H2 2024. Preliminary Q4 results show $509M annual revenue. This is a slight increase from estimates but a 5% year-on-year decline. NovoCure's valuation struggles with tepi...

2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...

NovoCure Limited (NASDAQ: NVCR) is one of today's top gainers. The company's shares have moved 3.24% on the day to $13.05. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company...

2024-01-18 07:24:27 ET More on NovoCure, Zai Lab, etc. Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) NovoCure: Significant Upside Even Without A Breakthrough Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Novocure reports better-tha...

Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after plati...

2024-01-12 16:40:04 ET Gainers: Outset Medical ( OM ) +11% . Kandi Technologies Group ( KNDI ) +7% . Dyne Therapeutics ( DYN ) +5% . Revance Therapeutics ( RVNC ) +4% . NovoCure Limited ( NVCR ) +3% . Losers: Gritstone&#x...